Last updated: February 25, 2026
What is NDC 31722-0504?
NDC 31722-0504 identifies a specific drug product. Based on publicly available sources, this NDC corresponds to Loxo-305 (LOXO-305), a Bruton tyrosine kinase (BTK) inhibitor developed for the treatment of B-cell malignancies, notably chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). It is currently in clinical trial stages and not yet approved for general commercial distribution.
Market Size and Potential
Target Conditions and Market Scope
- Chronic Lymphocytic Leukemia (CLL): Over 170,000 cases in the U.S. (SEER data, 2021).
- Mantle Cell Lymphoma (MCL): Approximately 2,000 new cases annually in the U.S.
- Other indications: Possible expansion to other B-cell malignancies.
Competitive Landscape
| Drug Name |
Mechanism |
Approval Status |
Estimated Global Sales (2022) |
Key Competitors |
| Ibrutinib (Imbruvica) |
BTK inhibitor |
Approved (2013) |
$8.17 billion (IQVIA) |
Acalabrutinib, Zanubrutinib, Orelabrutinib |
| Acalabrutinib (Calquence) |
BTK inhibitor |
Approved (2017) |
$1.3 billion |
Ibrutinib, Zanubrutinib |
| Zanubrutinib (Brukinsa) |
BTK inhibitor |
Approved (2019) |
$826 million |
Ibrutinib, Acalabrutinib |
| Loxo-305 (LOXO-305) |
BTK inhibitor |
Clinical Phase 2 |
Not yet commercialized |
Same class competitors in ongoing trials |
Market Drivers
- Increasing adoption of targeted therapies.
- Resistance to existing BTK inhibitors.
- Geographical expansion of clinical trials.
- Patent exclusivity duration: Likely until 2030-2035 depending on patent filings and extensions.
Challenges
- Entry barriers due to established competitors.
- Clinical trial success dependency.
- Cost of therapy: BTK inhibitors currently priced around $100,000 annually.
Price Projections
Current Pricing Dynamics
- Ibrutinib (brand Imbruvica): Average wholesale price (AWP) around $13,000 per month (approx. $156,000 annually).
- Acalabrutinib: AWP similar, slightly lower due to newer entry.
- Zanubrutinib: Slightly lower than Ibrutinib, roughly $12,000–$13,000/month.
Proposed Pricing Range for Loxo-305
- Phase 2 Pricing: Positioning at 70-80% of Ibrutinib to gain market share, likely initial pricing in the range of $8,000 to $10,000 per month (approx. $96,000–$120,000 annually).
- Market Penetration Strategy: Start with a premium pricing model for high-efficacy or resistance cases; consider discounts for second-line therapy.
Long-term Price Trajectories
- As patent protection expires, prices tend to decline 20-30% over 5-7 years due to biosimilar and generic competition.
- New entrants targeting resistant cases or offering improved safety profiles may command premiums for niche segments.
Revenue Projections (2023–2030)
| Year |
Estimated Market Penetration |
Projected Sales (USD) |
Assumptions |
| 2023 |
5% of total B-cell malignancies |
$100-150 million |
Early clinical approval in select regions |
| 2025 |
15% |
$300-500 million |
Increasing clinical data + expansion |
| 2027 |
30% |
$600-1 billion |
Broadened indication list, formulary inclusion |
| 2030 |
50% |
$1.5-2 billion |
Market dominance among BTK inhibitors |
Note: These projections assume successful clinical development, regulatory approval, and market penetration aligned with competitor launches.
Regulatory and Market Entry Considerations
- Approval pathways depend on phase 2/3 clinical trial outcomes.
- Orphan drug designation could expedite approval for rare indications like MCL.
- Personalized medicine approaches could influence pricing and reimbursement strategies.
Key Takeaways
- NDC 31722-0504 (Loxo-305) is a BTK inhibitor in clinical development targeting B-cell malignancies.
- The potential market could reach $1.5–2 billion annually by 2030.
- Initial pricing is likely to be in the $8,000–$10,000/month range.
- Competition from established BTK inhibitors offers significant market entry hurdles.
- Long-term pricing will decline as biosimilars and generics enter the market.
FAQs
-
When is Loxo-305 expected to receive FDA approval?
Pending clinical trial results, regulatory submission could occur between 2024 and 2026.
-
What factors influence the future pricing of Loxo-305?
Clinical efficacy, safety profile, competition, patent status, and payer negotiations.
-
How does Loxo-305 differentiate from existing BTK inhibitors?
Potential improvements in safety, resistance management, and clinical efficacy.
-
What are the main hurdles for market penetration?
Established competitors, clinical trial success, regulatory approval, and reimbursement policies.
-
What is the likely timeline for market entry?
Clinical trials are ongoing; commercialization could occur 2–3 years post-approval, around 2025–2027.
References
[1] Surveillance, Epidemiology, and End Results (SEER) Program. (2021). Cancer stat facts: Chronic lymphocytic leukemia. National Cancer Institute.
[2] IQVIA. (2022). Pharmaceutical Market Data.
[3] FDA. (2022). Drug development and approval timelines. U.S. Food and Drug Administration.
[4] EvaluatePharma. (2022). World Preview 2022.
[5] PWC. (2021). The future of targeted oncology therapies. Price & reimbursement strategies.
Note: All data are projections and estimates based on publicly available sources and market dynamics. Actual market conditions may vary.
